TD Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.5M | Sell |
|
|||||
|
2025
Q1 | $5.01M | Buy |
|
|||||
|
2024
Q4 | $3.93M | Sell |
|
|||||
|
2024
Q3 | $9.2M | Buy |
|
|||||
|
2024
Q2 | $6.13M | Sell |
|
|||||
|
2024
Q1 | $10.3M | Sell |
|
|||||
|
2023
Q4 | $10.6M | Buy |
|
|||||
|
2023
Q3 | $7.32M | Buy |
|
|||||
|
2023
Q2 | $5.43M | Buy |
|
|||||
|
2023
Q1 | $3.96M | Sell |
|
|||||
|
2022
Q4 | $6.03M | Sell |
|
|||||
|
2022
Q3 | $10.6M | Sell |
|
|||||
|
2022
Q2 | $18.1M | Sell |
|
|||||
|
2022
Q1 | $26M | Sell |
|
|||||
|
2021
Q4 | $31.4M | Buy |
|
|||||
|
2021
Q3 | $22M | Buy |
|
|||||
|
2021
Q2 | $18.7M | Buy |
|
|||||
|
2021
Q1 | $25.9M | Buy |
|
|||||
|
2020
Q4 | $25M | Buy |
|
|||||
|
2020
Q3 | $11.2M | Buy |
|
|||||
|
2020
Q2 | $8.63M | Buy |
|
|||||
|
2020
Q1 | $3.15M | Sell |
|
|||||
|
2019
Q4 | $3.04M | Sell |
|
|||||
|
2019
Q3 | $3.22M | Sell |
|
|||||
|
2019
Q2 | $5.28M | Buy |
|
|||||
|
2019
Q1 | $4.5M | Buy |
|
|||||
|
2018
Q4 | $2.5M | Sell |
|
|||||
|
2018
Q3 | $4.51M | Sell |
|
|||||
|
2018
Q2 | $4.57M | Buy |
|
|||||
|
2018
Q1 | $2.35M | Buy |
|
|||||
|
2017
Q4 | $1.92M | Buy |
|
|||||
|
2017
Q3 | $1.69M | Sell |
|
|||||
|
2017
Q2 | $2.34M | Buy |
|
|||||
|
2017
Q1 | $2.45M | Sell |
|
|||||
|
2016
Q4 | $2.72M | Buy |
|
|||||
|
2016
Q3 | $2.74M | Buy |
|
|||||
|
2016
Q2 | $1.63M | Buy |
|
|||||
|
2016
Q1 | $1.73M | Sell |
|
|||||
|
2015
Q4 | $3.17M | Sell |
|
|||||
|
2015
Q3 | $2.79M | Buy |
|
|||||
|
2015
Q2 | $2.5M | Hold |
|
|||||
|
2015
Q1 | $1.52M | Buy |
|
|||||
|
2014
Q4 | $984K | Buy |
|
|||||
|
2014
Q3 | $1.07M | Buy |
|
|||||
|
2014
Q2 | – | Sell |
|
|||||
|
2014
Q1 | $284K | Buy |
|